These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29039712)

  • 1. The management of refractory carcinoid syndrome: challenges and opportunities ahead.
    Cives M; Pellè E; Silvestris F
    J Med Econ; 2018 Mar; 21(3):241-243. PubMed ID: 29039712
    [No Abstract]   [Full Text] [Related]  

  • 2. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
    Alberts AS; Falkson G
    S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful symptomatic treatment of malignant carcinoid syndrome with the somatostatin analogue SMS 201-995.
    van Houten AA; Nortier JW; Vendrik CP
    Neth J Med; 1988 Apr; 32(3-4):194-8. PubMed ID: 2896307
    [No Abstract]   [Full Text] [Related]  

  • 5. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The carcinoid syndrome.
    Oates JA
    N Engl J Med; 1986 Sep; 315(11):702-4. PubMed ID: 2875390
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid reversal of carcinoid crisis with a somatostatin analogue.
    Kvols LK; Martin JK; Marsh HM; Moertel CG
    N Engl J Med; 1985 Nov; 313(19):1229-30. PubMed ID: 2865675
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.
    Joish VN; Frech F; Lapuerta P
    J Med Econ; 2018 Feb; 21(2):182-188. PubMed ID: 28959913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
    Altman AR; Tschen JA; Rice L
    Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity.
    Roy RC; Carter RF; Wright PD
    Anaesthesia; 1987 Jun; 42(6):627-32. PubMed ID: 2887127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogues do not prevent carcinoid crisis.
    Guo LJ; Tang CW
    Asian Pac J Cancer Prev; 2014; 15(16):6679-83. PubMed ID: 25169508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome.
    Ahlman H; Ahlund L; Dahlström A; Nilsson O; Skolnik G; Tisell LE; Tylén U
    Br J Cancer; 1987 Dec; 56(6):840-2. PubMed ID: 2893640
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.
    Kiesewetter B; Duan H; Lamm W; Haug A; Riss P; Selberherr A; Scheuba C; Raderer M
    Oncologist; 2019 Feb; 24(2):255-258. PubMed ID: 30171068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment.
    Gregor M
    Digestion; 1994; 55 Suppl 3():60-3. PubMed ID: 7698539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide--a synthetic somatostatin.
    Med Lett Drugs Ther; 1989 Jul; 31(796):66-8. PubMed ID: 2567960
    [No Abstract]   [Full Text] [Related]  

  • 16. [Analogs of somatostatin and carcinoid tumors].
    Gutiérrez Rodero F; Morales Cano JM; de Blas Laborda C; González Barber A
    Med Clin (Barc); 1990 Jun; 95(2):78-9. PubMed ID: 2250512
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
    Janson ET; Oberg K
    Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of musculoskeletal symptoms in the carcinoid syndrome after treatment with the somatostatin analog octreotide.
    Smith S; Anthony L; Roberts LJ; Oates JA; Pincus T
    Ann Intern Med; 1990 Jan; 112(1):66-8. PubMed ID: 2293820
    [No Abstract]   [Full Text] [Related]  

  • 19. Octreotide treatment of carcinoid hypertensive crisis.
    Warner RR; Mani S; Profeta J; Grunstein E
    Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carcinoid tumor--diagnostic and therapeutic problems].
    Batowski S; Bielewicz A
    Pol Tyg Lek; 1994 Jun 6-13; 49(23-24):536-7. PubMed ID: 7675710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.